Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04246047 · OUTCOME

Number of Participants With Clinically Significant Changes in Clinical Chemistry

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-04-23

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 73 months

What was measured

Blood samples will be collected for the analysis of clinical chemistry parameters.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2027-06
denom Units Selected
Participants
description
Blood samples will be collected for the analysis of clinical chemistry parameters.
reporting Status
NOT_POSTED
time Frame
Up to 73 months
title
Number of Participants With Clinically Significant Changes in Clinical Chemistry
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice